Scientific Reports (Aug 2021)

Insulin-like growth factor-1 level is a poor diagnostic indicator of growth hormone deficiency

  • Hideyuki Iwayama,
  • Sachiko Kitagawa,
  • Jyun Sada,
  • Ryosuke Miyamoto,
  • Tomohito Hayakawa,
  • Yoshiyuki Kuroyanagi,
  • Taichiro Muto,
  • Hirokazu Kurahashi,
  • Wataru Ohashi,
  • Junko Takagi,
  • Akihisa Okumura

DOI
https://doi.org/10.1038/s41598-021-95632-0
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 6

Abstract

Read online

Abstract We evaluated the diagnostic accuracy of insulin-like growth factor-1 (IGF-1) for screening growth hormone deficiency (GHD) to determine the usefulness of IGF-1 as a screening test. Among 298 consecutive children who had short stature or decreased height velocity, we measured IGF-1 levels and performed growth hormone (GH) secretion test using clonidine, arginine, and, in cases with different results of the two tests, L-dopa. Patients with congenital abnormalities were excluded. GHD was defined as peak GH ≤ 6.0 ng/mL in the two tests. We identified 60 and 238 patients with and without GHD, respectively. The mean IGF-1 standard deviation (SD) was not significantly different between the GHD and non-GHD groups (p = 0.23). Receiver operating characteristic curve analysis demonstrated the best diagnostic accuracy at an IGF-1 cutoff of − 1.493 SD, with 0.685 sensitivity, 0.417 specificity, 0.25 positive and 0.823 negative predictive values, and 0.517 area under the curve. Correlation analysis revealed that none of the items of patients’ characteristics increased the diagnostic power of IGF-1. IGF-1 level had poor diagnostic accuracy as a screening test for GHD. Therefore, IGF-1 should not be used alone for GHD screening. A predictive biomarker for GHD should be developed in the future.